FASLG and neoplasm: This may be associated with the downregulation or masking of the MHCII on DCs by CD4+ T cell EVs and induction of apoptosis in Fas expressing DCs via the Fas/FasL pathway.15 In this study, DCs were first treated with CD4+ T cell EVs, then these immunoregulatory DCs were used to treat tumor‐bearing mice.